5.3 C
New York
Saturday, March 2, 2024

Moderna doesn’t expect Covid vaccine data for young children until 2022, CEO says

  • Moderna has already begun a study testing the vaccine in adolescents as young as 12, and CEO Stephane Bancel expects that study will be done by the time the fall semester starts in September.
  • It expects to start a study for young children between ages 1 and 11 "soon," but Bancel said that study will take "much longer."
  • Moderna's vaccine has been authorized by the Food and Drug Administration for use in people who are 18 years old and older.

In this article

A nurse prepares a syringe with the COVID-19 Moderna vaccine for a worker of the New York City Fire Department Bureau of Emergency Medical Services (FDNY EMS), amid the coronavirus disease (COVID-19) pandemic in New York, December 23, 2020.Carlo Allegri | Reuters

Moderna doesn't expect to have clinical trial data on its coronavirus vaccine in young children until 2022, CEO Stephane Bancel said Monday.

Moderna's vaccine has been authorized by the Food and Drug Administration for use in people who are 18 years old and older. Clinical trial studies testing the vaccine in kids, whose immune systems can respond differently than adults, still need to be completed.

The company has already begun a study testing the vaccine in adolescents as young as 12, and Bancel expects that study will be done by the time the fall semester starts in September. It expects to start a study for young children between ages 1 and 11 "soon," but Bancel said that study will take "much longer."

Related Articles

Latest Articles